BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Cheng CH, Hao WR, Cheng TH. Elafibranor: A promising therapeutic approach for liver fibrosis and gut barrier dysfunction in alcohol-associated liver disease. World J Gastroenterol 2025; 31(3): 98783 [PMID: 39839906 DOI: 10.3748/wjg.v31.i3.98783]
URL: https://www.wjgnet.com/1948-5182/full/v31/i3/98783.htm
Number Citing Articles
1
Weichao Zhong, Lidan Luo, Yaqing Liu, Furong Huang, Quan Meng, Guanghui Deng, Yunjia Li, Xingning Liu, Guangdong Tong, Yufeng Xing. TRIM21 Alleviates Alcoholic Liver Fibrosis by Inhibiting Ferroptosis Through Regulation of IDO1 UbiquitinationThe FASEB Journal 2026; 40(8) doi: 10.1096/fj.202504920R
2
Rong Hu, Dan Liu, Xiaofei Sun, Zhong Yu. New drugs approved by European medicines agency during 2024European Journal of Medicinal Chemistry 2025; 294: 117761 doi: 10.1016/j.ejmech.2025.117761
3
Yue Feng, PanShiLi Han, Tao Liu, YanHang Gao. MetALD: new insights and unraveling therapeutic potentialMetabolism and Target Organ Damage 2025; 5(3) doi: 10.20517/mtod.2025.65
4
Pascal Pellegrini, Thomas Gelbrich, Marijan Stefinovic, Sven Nerdinger, Doris E. Braun. From Structure to Stability: Exploring the Solid-State Forms of a Novel First-In-Class PPAR Agonist (Elafibranor)Crystal Growth & Design 2025; 25(16): 6892 doi: 10.1021/acs.cgd.5c00844